Heron Therapeutics Inc HRTX

NAS: HRTX | ISIN: US4277461020 14/11/2024

1,240 USD (+2,48%)

(+2,48%) 14/11/2024

Grafiek Heron Therapeutics Inc

Grafiek Heron Therapeutics Inc

1 dag1d 2,48%
1 week1w -29,14%
1 maand1m -31,11%
3 maanden3m -36,41%
6 maanden6m -58,67%
1 jaar1j 44,19%
5 jaar5j -94,25%

Heron Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

3 september 2024 · Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer · Persbericht

6 augustus 2024 · Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance · Persbericht

30 juli 2024 · Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 · Persbericht

15 juli 2024 · Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System · Persbericht

2 juli 2024 · Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") · Persbericht

29 mei 2024 · Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") · Persbericht

7 mei 2024 · Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates · Persbericht

24 april 2024 · Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 · Persbericht

11 april 2024 · Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City · Persbericht

28 maart 2024 · Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

Profiel Heron Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.herontx.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Barry Quart

Werknemers: 283

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe